The relationship between using estrogen and/or progesterone and the risk of mammary gland hyperplasia in women: a meta-analysis

Gynecol Endocrinol. 2022 Jul;38(7):543-547. doi: 10.1080/09513590.2022.2076831. Epub 2022 May 23.

Abstract

Background: As reported that the usage of estrogen and/or progesterone increases the risk of mammary gland hyperplasia (MGH) with conflicting results. Therefore, we conducted a meta-analysis to higher elucidate the relationship between hormones and MGH.

Method: PubMed, Embase, Web of Science, Cochrane Library, Chinese National Knowledge Infrastructure, and Wan-fang database were searched for studies until April 28, 2021.

Results: Nine related studies were included in the present meta-analysis. We found that the usage of estrogen and/or progesterone had a significant association with increasing the risk of MGH (RR = 1.56, 95% CI: 1.13-2.15, p = .000). The subgroup results showed that the risk of MGH increased in the Mix population (RR = 1.72, CI: 1.58-1.88, p < .001) but no significant difference in the Asian population. Meanwhile, as for using estrogen plus progesterone (EPP) and postmenopausal women the risk of MGH, respectively, increased (RR = 1.74, CI: 1.22-2.47, p = .002) and (RR = 1.75, CI: 1.24-2.47, p = .001) but no significant different for using estrogen alone and premenopausal women.

Conclusions: This study findings indicated that using estrogen and/or progesterone might increase the risk of MGH in premenopausal and postmenopausal women.

Keywords: Hormone; estrogen; mammary gland hyperplasia; progesterone; 乳腺增生; 孕激素; 激素; 雌激素.

Publication types

  • Meta-Analysis

MeSH terms

  • Estrogens / adverse effects
  • Female
  • Humans
  • Hyperplasia
  • Mammary Glands, Human*
  • Premenopause
  • Progesterone*

Substances

  • Estrogens
  • Progesterone